 Genfit NASDAQ: GNFT, a late-stage biopharmaceutical company, reported some disappointing news on Monday regarding one of its leading pipeline candidates, Elafibranor. Genfits shares are down by 65.2 as of 12:46 p.m. EDT on Tuesday. Interim analysis of RESOLVE-IT -- a phase 3 clinical trial evaluating Elafibranor in NASH patients -- showed that the treatment failed to achieve statistically significant NASH resolution without worsening of fibrosis scarring in the lungs at week 72, which was the primary endpoint of the study. 